Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVACC: Olaparib, Durvalumab and UV1 as Maintenance Therapy in Recurrent Ovarian Cancer
NCT04742075Phase 2Active, not recruiting
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Dec 2021
- Primary completion
- May 2026
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of UV1 in ovarian cancer, sponsored by Nordic Society of Gynaecological Oncology Clinical Trial Unit. Started Dec 2021; status: active, not recruiting.
02
Drugs
UV1
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04742075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742075.